Healix is Now a National Provider of Trogarzo™ (ibalizumab-uiyk)

Healix is Now a National Provider of Trogarzo™ (ibalizumab-uiyk)

SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the...
Outpatient Treatment of Osteomyelitis with Telavancin

Outpatient Treatment of Osteomyelitis with Telavancin

SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in...